Regeneron Pharmaceuticals Inc (REGN) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $2.82 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.17. Analysts had a consensus of $2.65. The company posted revenue of $1213.00 million in the period, compared to analysts expectations of $1237.52 million. The company’s revenue was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.89 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016.
Regeneron Pharmaceuticals Inc opened for trading at $435.27 and hit $437.85 on the upside on Tusday, eventually ending the session at $434.9, with a gain of 0.21% or 0.9 points. The heightened volatility saw the trading volume jump to 12,51,045 shares. Company has a market cap of $45,699 M.
In a different news, on Aug 1, 2016, Joseph L Goldstein (director) sold 2,125 shares at $425.00 per share price. According to the SEC, on May 25, 2016, Arthur F Ryan (director) sold 1,000 shares at $396.64 per share price. On May 19, 2016, Plew Daniel P Van (EVP & General Mgr Industrial O) sold 4,413 shares at $385.77 per share price, according to the Form-4 filing with the securities and exchange commission.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.